HC Wainwright Has Bullish Forecast for CRBP Q1 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now anticipates that the biopharmaceutical company will post earnings of ($0.98) per share for the quarter, up from their previous forecast of ($1.33). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.13) EPS, FY2025 earnings at ($4.20) EPS, FY2026 earnings at ($4.57) EPS, FY2027 earnings at ($5.47) EPS, FY2028 earnings at ($4.37) EPS and FY2029 earnings at ($2.14) EPS.

CRBP has been the topic of a number of other reports. StockNews.com upgraded Corbus Pharmaceuticals to a “sell” rating in a report on Thursday, March 6th. Piper Sandler began coverage on Corbus Pharmaceuticals in a report on Monday, December 2nd. They issued an “overweight” rating and a $35.00 target price on the stock. William Blair started coverage on Corbus Pharmaceuticals in a report on Friday, February 28th. They issued an “outperform” rating on the stock. Jefferies Financial Group lowered their price target on Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Finally, Wedbush reiterated an “outperform” rating and set a $51.00 price target on shares of Corbus Pharmaceuticals in a report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.13.

Corbus Pharmaceuticals Stock Performance

CRBP opened at $6.96 on Monday. Corbus Pharmaceuticals has a one year low of $6.38 and a one year high of $61.90. The stock’s fifty day moving average is $9.32 and its 200-day moving average is $18.10. The company has a market capitalization of $84.77 million, a PE ratio of -1.48 and a beta of 2.63.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.24.

Institutional Trading of Corbus Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Vestcor Inc acquired a new position in shares of Corbus Pharmaceuticals during the third quarter valued at about $64,000. Wells Fargo & Company MN grew its position in Corbus Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 2,195 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Corbus Pharmaceuticals during the 4th quarter valued at approximately $84,000. Deutsche Bank AG grew its position in shares of Corbus Pharmaceuticals by 46.8% during the 4th quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 2,616 shares during the period. Finally, Aquatic Capital Management LLC bought a new position in shares of Corbus Pharmaceuticals during the 4th quarter valued at approximately $101,000. Institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.